Catalyst Pharmaceuticals (NASDAQ: CPRX) CEO reports RSU vesting and tax share withholding

Rhea-AI Filing Summary

Catalyst Pharmaceuticals President and CEO Richard J. Daly reported equity compensation activity. On January 5, 2026, 42,105 restricted stock units vested and were converted into an equal number of Catalyst common shares at a price of $0 per share. According to the filing, this award vests in five equal annual tranches from January 1, 2025 through January 1, 2029.

To cover withholding taxes tied to the vesting, the company withheld 10,577 common shares, leaving Daly with 271,266 common shares directly owned after the transactions. He also reported 2,618,539 restricted stock units beneficially owned following this vesting event.

Insider Trade Summary

42,105 shares exercised/converted

Mixed 3 txns

Insider Daly Richard J

Role President and CEO

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	42,105	$0.00	--
Exercise	Common Stock, par value $0.001 per share	42,105	$0.00	--
Tax Withholding	Common Stock, par value $0.001 per share	10,577	$0.00	--

Holdings After Transaction: Restricted Stock Units — 2,618,539 shares (Direct); Common Stock, par value $0.001 per share — 281,843 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted common stock. Derivative securities vest in equal tranches, 1/5th on January 1, 2025, 1/5th on January 1, 2026, 1/5th on January 1, 2027, 1/5th on January 1, 2028, and 1/5th on January 1, 2029. Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The second tranche of shares was delivered on January 5, 2026.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Daly Richard J

(Last) (First) (Middle)

355 ALHAMBRA CIRCLE

SUITE 801

(Street)

CORAL GABLES FL 33134

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CATALYST PHARMACEUTICALS, INC. [ CPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.001 per share	01/05/2026		M		42,105	A	(1)	281,843	D
Common Stock, par value $0.001 per share	01/05/2026		F		10,577	D	(2)	271,266	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	01/05/2026		M			42,105	(3)	(4)	Common Stock	42,105	$0	2,618,539	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.

2. Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted common stock.

3. Derivative securities vest in equal tranches, 1/5th on January 1, 2025, 1/5th on January 1, 2026, 1/5th on January 1, 2027, 1/5th on January 1, 2028, and 1/5th on January 1, 2029.

4. Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The second tranche of shares was delivered on January 5, 2026.

	/s/ Richard J. Daly	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CPRX President and CEO Richard J. Daly report?

Richard J. Daly reported the vesting and conversion of 42,105 restricted stock units into Catalyst Pharmaceuticals common stock on January 5, 2026, at an exercise price of $0 per share.

How many Catalyst Pharmaceuticals (CPRX) shares were withheld for taxes?

The company withheld 10,577 shares of common stock to satisfy applicable withholding taxes upon vesting of restricted stock, as described in the footnotes.

How many Catalyst Pharmaceuticals (CPRX) shares does Richard J. Daly own after this Form 4?

After the reported transactions, Richard J. Daly directly owned 271,266 shares of common stock, as shown in the non-derivative table.

What is the vesting schedule for Richard J. Daly’s restricted stock units at CPRX?

The restricted stock units vest in five equal tranches: 1/5th on January 1, 2025, 1/5th on January 1, 2026, 1/5th on January 1, 2027, 1/5th on January 1, 2028, and 1/5th on January 1, 2029.

How many restricted stock units does Richard J. Daly hold after this CPRX transaction?

Following the reported derivative transaction, Richard J. Daly beneficially owned 2,618,539 restricted stock units, each representing a contingent right to receive one share of common stock upon vesting.

When were the vested CPRX shares delivered to Richard J. Daly?

The footnotes state that shares of common stock are required to be delivered within sixty days of vesting and that the second tranche of shares was delivered on January 5, 2026.